Marina Biotech, Inc. (OTCMKTS:MRNA)’s share price rose 5% during mid-day trading on Monday . The company traded as high as $25.94 and last traded at $25.84. Approximately 632,468 shares were traded during trading, a decline of 38% from the average daily volume of 1,013,709 shares. The stock had previously closed at $24.61.

Several brokerages have weighed in on MRNA. Piper Jaffray Companies began coverage on shares of Marina Biotech in a research note on Wednesday, January 2nd. They issued an “overweight” rating and a $24.00 target price for the company. Barclays began coverage on shares of Marina Biotech in a research note on Wednesday, January 2nd. They issued an “overweight” rating and a $20.00 target price for the company. Goldman Sachs Group began coverage on shares of Marina Biotech in a research note on Wednesday, January 2nd. They issued a “buy” rating and a $25.00 target price for the company. Oppenheimer began coverage on shares of Marina Biotech in a research note on Wednesday, January 2nd. They issued an “outperform” rating and a $27.00 target price for the company. Finally, Bank of America began coverage on shares of Marina Biotech in a research note on Wednesday, January 2nd. They issued a “buy” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Marina Biotech has an average rating of “Buy” and an average price target of $26.11.

An institutional investor recently bought a new position in Marina Biotech stock. Canada Pension Plan Investment Board bought a new position in shares of Marina Biotech, Inc. (OTCMKTS:MRNA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,600,000 shares of the biotechnology company’s stock, valued at approximately $24,430,000. Canada Pension Plan Investment Board owned about 0.49% of Marina Biotech at the end of the most recent reporting period.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2019/04/15/marina-biotech-mrna-stock-price-up-5.html.

Marina Biotech Company Profile (OTCMKTS:MRNA)

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

Recommended Story: Trading Strategy Examples and Plans

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.